NeurologyLive® Friday 5 — January 5, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 5, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: 5 Clinical Trial Readouts in Neurology to Look for in 2024

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

5 Clinical Trial Readouts in Neurology to Look for in 2024

2: Preclinical Neuroinflammation Modulation and Neuroprotection With Fosgonimeton in AD: Kevin Church, PhD

The chief scientific officer at Athira Pharma talked about preclinical results presented at the 2023 Society for Neuroscience Annual Meeting on fosgonimeton, a potential treatment for Alzheimer disease and other neurodegenerative diseases. [WATCH TIME: 6 minutes]

Preclinical Neuroinflammation Modulation and Neuroprotection With Fosgonimeton in AD: Kevin Church, PhD

3: FDA Action Update, December 2023: Approval and Clearances

Catch up on any of the neurology news headlines you may have missed over the course of December 2023, compiled all into one place by the NeurologyLive® team.

FDA Action Update, December 2023: Approval and Clearances

4: NeuroVoices: Jennifer Gudeman, PharmD, on the Effect of Once-Nightly Sodium Oxybate in Narcolepsy Subtypes

The senior vice president of medical and clinical affairs for Avadel Pharmaceuticals provided perspective on a recently published analysis demonstrating the benefits of once-nightly sodium oxybate in narcolepsy type 1 and type 2.

NeuroVoices: Jennifer Gudeman, PharmD, on the Effect of Once-Nightly Sodium Oxybate in Narcolepsy Subtypes

5: A Dive Into the Neurological Impact of Long COVID and Hyperbaric Oxygen Therapy: Amir Hadanny, MD, PhD

The chief medical research officer and head of research at Aviv Clinics discussed the impact of long COVID on patients and shared findings from a recently published study on using hyperbaric oxygen therapy protocol as a treatment for these patients. [WATCH TIME: 8 minutes]

A Dive Into the Neurological Impact of Long COVID and Hyperbaric Oxygen Therapy: Amir Hadanny, MD, PhD
Related Videos
Shadi Yaghi, MD, associate professor of neurology at Brown University
Matthew B. Harms, MD, MDA Medical Advisor and Care Center Director, Associate Professor of Neurology at Columbia University Irving Medical Center - Eleanor and Lou Gehrig ALS Center.
Ava L. Liberman, MD, medical director of the Stroke Center at Weill Cornell Medicine
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.